A Meta-analysis of the relation between chemokine receptor 5 delta32 polymorphism and multiple sclerosis susceptibility

Immunological Investigations

Volumn 43, Issue 4, 2014, Pages 299-311

  Song, Gwan Gyu ^a   Lee, Young Ho ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

CCR5 32 polymorphism; Meta analysis; Multiple sclerosis

Indexed keywords

CHEMOKINE RECEPTOR CCR5;

ALLELE; ARAB; ARTICLE; CHEMOKINE RECEPTOR 5 DELTA32 GENE; DNA POLYMORPHISM; DOMINANT INHERITANCE; ETHNIC GROUP; EUROPEAN AMERICAN; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HUMAN; MULTIPLE SCLEROSIS; PREVALENCE; PRIORITY JOURNAL; PUBLISHING; RECEPTOR GENE; RECESSIVE INHERITANCE; SYSTEMATIC REVIEW; CAUCASIAN; DISEASE COURSE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; META ANALYSIS; RISK;

ALLELES; DISEASE PROGRESSION; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; ODDS RATIO; POLYMORPHISM, GENETIC; PUBLICATION BIAS; RECEPTORS, CCR5;

EID: 84897978799     PISSN: 08820139     EISSN: 15324311     Source Type: Journal    
DOI: 10.3109/08820139.2013.845204     Document Type: Article

References (32)

1. Barcellos LF, Schito AM, Rimmler JB, et al. (2000). CC-chemokine receptor 5 polymorphism and age of onset in familial multiple sclerosis. Multiple Sclerosis Genetics Group. Immunogenetics, 51, 281-8. (Pubitemid 30198882)
2. Benkirane M, Jin DY, Chun RF, et al. (1997). Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5delta32. J Biol Chem, 272, 30603-6. (Pubitemid 27527488)
3. Bennetts BH, Teutsch SM, Buhler MM, et al. (1997). The CCR5 deletion mutation fails to protect against multiple sclerosis. Hum Immunol, 58, 52-9. (Pubitemid 28027413)
4. D'Angelo R, Crisafulli C, Rinaldi C, et al. (2011). CCR5Delta32 polymorphism associated with a slower rate disease progression in a cohort of RR-MS Sicilian patients. Mult Scler Int, 2011, 1-6.
5. Davey Smith G, Egger M. (1997). Meta-analyses of randomised controlled trials. Lancet, 350, 1182.
6. DerSimonian R, Laird N. (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88. (Pubitemid 17189972)
7. Egger M, Davey Smith G, Schneider M, Minder C. (1997). Bias in meta-analysis detected by a simple, graphical test. Br Med J, 315, 629-34. (Pubitemid 27387172)
8. Favorova OO, Andreewski TV, Boiko AN, et al. (2002). The chemokine receptor CCR5 deletion mutation is associated with MS in HLA-DR4-positive Russians. Neurology, 59, 1652-5. (Pubitemid 35387082)
9. Favorova OO, Favorov AV, Boiko AN, et al. (2006). Three allele combinations associated with multiple sclerosis. BMC Med Genet, 7, 63.
10. Haase CG, Schmidt S, Faustmann PM. (2002). Frequencies of the G-protein beta3 subunit C825T polymorphism and the delta 32 mutation of the chemokine receptor-5 in patients with multiple sclerosis. Neurosci Lett, 330, 293-5. (Pubitemid 35254056)
11. Higgins JP, Thompson SG. (2002). Quantifying heterogeneity in a meta-analysis. Stat Med, 21, 1539-58. (Pubitemid 34746062)
12. Hoppenbrouwers IA, Hintzen RQ. (2011). Genetics of multiple sclerosis. Biochim Biophys Acta, 1812, 194-201.
13. Kaimen-Maciel DR, Reiche EM, Brum Souza DG, et al. (2007). CCR5-Delta32 genetic polymorphism associated with benign clinical course and magnetic resonance imaging findings in Brazilian patients with multiple sclerosis. Int J Mol Med, 20, 337-44.
14. Kallaur AP, Kaimen-Maciel DR, Morimoto HK, et al. (2011). Genetic polymorphisms associated with the development and clinical course of multiple sclerosis (review). Int J Mol Med, 28, 467-79.
15. Kantarci OH, Morales Y, Ziemer PA, et al. (2005). CCR5Delta32 polymorphism effects on CCR5 expression, patterns of immunopathology and disease course in multiple sclerosis. J Neuroimmunol, 169, 137-43. (Pubitemid 41527099)
16. Lee YH, Harley JB, Nath SK. (2006). Meta-analysis of TNF-alpha promoter-308 A/G polymorphism and SLE susceptibility. Eur J Hum Genet, 14, 364-71.
17. Lee YH, Ji JD, Song GG. (2007). Tumor necrosis factor-alpha promoter-308 A/G polymorphism and rheumatoid arthritis susceptibility: A metaanalysis. J Rheumatol, 34, 43-9. (Pubitemid 46106561)
18. Lee YH, Witte T, Momot T, et al. (2005). The mannose-binding lectin gene polymorphisms and systemic lupus erythematosus: Two case-control studies and a meta-analysis. Arthritis Rheum, 52, 3966-74. (Pubitemid 41798236)
19. Liu R, Paxton WA, Choe S, et al. (1996). Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell, 86, 367-77. (Pubitemid 26272077)
20. Lublin FD, Reingold SC. (1996). Defining the clinical course of multiple sclerosis: Results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology, 46, 907-11.
21. Luomala M, Lehtimaki T, Huhtala H, et al. (2003). Promoter polymorphism of IL-10 and severity of multiple sclerosis. Acta Neurol Scand, 108, 396-400. (Pubitemid 37464118)
22. Makarycheva OY, Tsareva EY, Sudomoina MA, et al. (2011). Family analysis of linkage and association of HLA-DRB1, CTLA4, TGFB1, IL4, CCR5, RANTES, MMP9 and TIMP1 gene polymorphisms with Multiple Sclerosis. Acta Naturae, 3, 85-92.
23. Nath SK, Harley JB, Lee YH. (2005). Polymorphisms of complement receptor 1 and interleukin-10 genes and systemic lupus erythematosus: A meta-analysis. Hum Genet, 118, 225-34. (Pubitemid 41672084)
24. Prahalad S. (2006). Negative association between the chemokine receptor CCR5-Delta32 polymorphism and rheumatoid arthritis: A meta-analysis. Genes Immun, 7, 264-8.
25. Ristic S, Lovrecic L, Starcevic-Cizmarevic N, et al. (2006). No association of CCR5delta32 gene mutation with multiple sclerosis in Croatian and Slovenian patients. Mult Scler, 12, 360-2. (Pubitemid 43827194)
26. Sellebjerg F, Kristiansen TB, Wittenhagen P, et al. (2007). Chemokine receptor CCR5 in interferon-treated multiple sclerosis. Acta Neurol Scand, 115, 413-18. (Pubitemid 46776327)
27. Shahbazi M, Ebadi H, Fathi D, et al. (2009). CCR5-delta 32 allele is associated with the risk of developing multiple sclerosis in the Iranian population. Cell Mol Neurobiol, 29, 1205-9.
28. Silversides JA, Heggarty SV, McDonnell GV, et al. (2004). Influence of CCR5 delta32 polymorphism on multiple sclerosis susceptibility and disease course. Mult Scler, 10, 149-52. (Pubitemid 38499906)
29. Szczucinski A, Losy J. (2007). Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies. Acta Neurol Scand, 115, 137-46. (Pubitemid 46219205)
30. Szekanecz Z, Kim J, Koch AE. (2003). Chemokines and chemokine receptors in rheumatoid arthritis. Semin Immunol, 15, 15-21. (Pubitemid 36092175)
31. Wedderburn LR, Robinson N, Patel A, et al. (2000). Selective recruitment of polarized T cells expressing CCR5 and CXCR3 to the inflamed joints of children with juvenile idiopathic arthritis. Arthritis Rheum, 43, 765-74.
32. Wu L, LaRosa G, Kassam N, et al. (1997). Interaction of chemokine receptor CCR5 with its ligands: Multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. J Exp Med, 186, 1373-81. (Pubitemid 27469033)